Paul J. Converse

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model”.

Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model

Antimicrobial Agents and Chemotherapy(2020)10.1128/aac.00259-20

N/A

0DataRank · unranked

34 citations

Paul J. Converse, Till F. Omansen, Sandeep Tyagi, Rokeya Tasneen, Jeongjun Kim +2 more

Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer

Antimicrobial Agents and Chemotherapy(2021)10.1128/aac.01418-21

N/A

0DataRank · unranked

17 citations

Deepak V. Almeida, Paul J. Converse, Till F. Omansen, Eric L. Nuermberger, Oliver Komm

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.22.449541

N/A

0DataRank · unranked

0 citations

Paul J. Converse, Oliver Komm, Eric L. Nuermberger, Deepak V. Almeida

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.06.22.449542

N/A

0DataRank · unranked

0 citations

Deepak V. Almeida, Paul J. Converse, Till F. Omansen, Eric L. Nuermberger, Oliver Komm

Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs

Nature Communications(2022)10.1038/s41467-022-33736-5

N/A

0DataRank · unranked

34 citations

Susan H. Davis, Sebastian Damerow, Curtis A. Engelhart, Michael Mathieson, Beatriz Baragaña +40 more

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.04.479214

N/A

0DataRank · unranked

11 citations

Maria Santos Martínez, Olalla Sanz, Beatriz Urones, Jorge Esquivias, Heena Soni +25 more

The Many Hosts of Mycobacteria 9 (MHM9): A conference report

Tuberculosis(2023)10.1016/j.tube.2023.102377

N/A

0DataRank · unranked

5 citations

Kathleen A. Alexander, Deepak V. Almeida, Matthew Z. Anderson, Ray L. Ball, Gillian Beamer +56 more